期刊
NATURE REVIEWS CANCER
卷 13, 期 10, 页码 685-700出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3580
关键词
-
类别
资金
- Swedish Cancer Society [12-0722, 12-0796]
- Children's Cancer Foundation [11/020, 10/065]
- Swedish Research Council [621-2011-5181, 521-2012-2831]
- Lions Cancer Society, Umea [LP 12-1946]
- JC Kempe Foundation
The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC). The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK. In this Review, we discuss our current understanding of ALK function in human cancer and the implications for tumour treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据